WS Investor
10 Nov 2026, 17:11
Agilent Expands Hematologic Cancer Profiling Portfolio with New Pan Heme NGS Solution
Agilent Technologies (NYSE: A) launched SureSelect Cancer Research Pan Heme, a new next-generation sequencing research solution designed for comprehensive genomic profiling of hematologic malignancies.
Developed with Roswell Park Comprehensive Cancer Center, the platform combines DNA and RNA profiling with automated sample preparation and integrated bioinformatics. It is designed to streamline molecular profiling workflows for blood cancers while reducing hands-on laboratory work.
SureSelect Cancer Research Pan Heme analyzes 359 DNA genes and 124 RNA genes and can assess several major genomic alteration classes, including single-nucleotide variants, insertions and deletions, copy-number variants, immunoglobulin translocations and gene fusions.
Agilent said Roswell Park’s current implementation of the integrated laboratory and informatics workflow can generate sample-to-report results in approximately 48 hours.
The system can also be paired with Agilent’s Magnis NGS Prep System for automated library preparation and target enrichment, while QIAGEN Clinical Insight supports variant analysis and reporting. Manual and semi-automated configurations are available for laboratories with different throughput requirements.
The launch expands Agilent’s cancer research portfolio alongside SureSelect Cancer Research CGP for solid tumors and SureSelect Human All Exon V8 for broader genomic profiling.
SureSelect Cancer Research Pan Heme is intended for research use only and is not approved for diagnostic procedures.
Agilent Technologies (NYSE: A) launched SureSelect Cancer Research Pan Heme, a new next-generation sequencing research solution designed for comprehensive genomic profiling of hematologic malignancies.
Developed with Roswell Park Comprehensive Cancer Center, the platform combines DNA and RNA profiling with automated sample preparation and integrated bioinformatics. It is designed to streamline molecular profiling workflows for blood cancers while reducing hands-on laboratory work.
SureSelect Cancer Research Pan Heme analyzes 359 DNA genes and 124 RNA genes and can assess several major genomic alteration classes, including single-nucleotide variants, insertions and deletions, copy-number variants, immunoglobulin translocations and gene fusions.
Agilent said Roswell Park’s current implementation of the integrated laboratory and informatics workflow can generate sample-to-report results in approximately 48 hours.
The system can also be paired with Agilent’s Magnis NGS Prep System for automated library preparation and target enrichment, while QIAGEN Clinical Insight supports variant analysis and reporting. Manual and semi-automated configurations are available for laboratories with different throughput requirements.
The launch expands Agilent’s cancer research portfolio alongside SureSelect Cancer Research CGP for solid tumors and SureSelect Human All Exon V8 for broader genomic profiling.
SureSelect Cancer Research Pan Heme is intended for research use only and is not approved for diagnostic procedures.
